Search
Milestone Pharmaceuticals Inc
MISTAdd to Watchlist
0.707USD
-0.088-11.07%
Close 10-16 16:00（ET）
88.02MMarket Cap
LossP/E TTM
After-hours 17:56 (ET)0.710USD+0.004+0.57%
After-hours 17:56 (ET)Milestone Pharmaceuticals Inc (MIST) Stock Price Target & Forecast
Analyst Rating
Based on 7 analysts giving stock ratings to Milestone Pharmaceuticals Inc in the past month.
Buy
1 Strong Buy
5 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
5.857USD+664.84%
MIST Analyst Recommendation Trends
In the current month, MIST has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. MIST average Analyst price target in the last month is 5.857.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
1
1
1
1
1
1
0
0
5
5
4
4
4
4
4
4
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
7
6
6
6
6
5
5
MIST Analyst Rating for Peer Comparison
Updated: Oct 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Insmed Inc
INSM
7
18
0
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
Revolution Medicines Inc
RVMD
9
14
1
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
7
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, MIST EPS is projected to reach -0.217 in FY2026Q3, following reported EPS of -0.206 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.16
0.31
-0.20
-0.22
-0.23
Actual
-0.16
-0.20
-0.21
--
--
Surprise
-2.61%
-165.24%
-5.80%
--
--
FAQs
What is Milestone Pharmaceuticals Inc's expected revenue for the next quarter?
Milestone Pharmaceuticals Inc's expected revenue is 1.14M.
What is Milestone Pharmaceuticals Inc's price target?
Analysts forecast that Milestone Pharmaceuticals Inc's price target is USD 5.86, with the highest forecast at USD 8.00 and the lowest forecast at USD 2.00.
How have Milestone Pharmaceuticals IncMIST's recent earnings per share performed?
The market expectation was USD -0.21, while Milestone Pharmaceuticals IncMIST's earnings per share (EPS) for the previous quarter was USD -0.20. EPS for the next quarter is expected at USD -0.22.
What is the analyst rating for Milestone Pharmaceuticals Inc?
Based on the ratings of Milestone Pharmaceuticals Inc's stock from 7 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.